Company news

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) news

Zentalis Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 1, 2026: Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule…

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) news

Press releases & updates

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering

Zentalis Pharmaceuticals Announces Pricing of Underwritten Public Offering

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4)

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026

Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer

Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026

Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary

Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer

Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Zentalis Pharmaceuticals Announces Key Management Appointments

Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib

Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies

Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024

Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress

Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program

Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors

Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments

Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates

Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer

Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock

Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing